Takeda initiates development of a plasma-derived therapy for COVID-19
Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.